BioServe's CEO Delivers Address to the GOT Summit on Novel Methods for Validating Case-Control Studies

BELTSVILLE, MD--(Marketwire - May 21, 2008) - As a featured speaker at the GOT Summit, Kevin Krenitsky MD, Chief Executive Officer of BioServe, yesterday delivered a presentation to a packed hall on novel methods for validating case-control studies.

One of the key challenges facing life science researchers is conducting case-control studies, currently a complex and expensive process. Now, research institutions of all types and sizes have an effective, economical solution at hand. "The application of richly annotated DNA samples to validate case-control studies has the potential to revolutionize how studies are currently carried out," remarked Dr. Krenitsky.

The conventional approach to case-control studies requires researchers to recruit, and procure thousands of cases and control samples from patients who already have the disease or condition in question, then look back to see if there are characteristics present in these patients that differ from those who don't have the disease. "The burden of consenting, collecting and processing patient samples with in-depth clinical and demographic data costs, at a minimum, hundreds of dollars per patient, and does not take into account the time it takes to undertake such collections," added Dr. Krenitsky.

"Given the time and costs involved with conducting case-control studies, it is essential that we find a way to validate results as quickly and as cost-effectively as possible."

The creation and application of matched DNA case-control studies in ready-made 96 and 384 well plate formats, across a wide range of diseases, presents a powerful new approach for researchers to efficiently validate case-control studies that lead to better diagnostic and therapeutic targets. Densely-annotated DNA on a plate promises to radically alter how researchers validate case-control studies. By lowering cost and complexity barriers to validating case-control studies with highly-annotated DNA samples, researchers will be able to vastly accelerate R&D programs and generate more credible outcomes that produce better diagnostics and therapeutics.

"BioServe has assembled a world-class biorepository from which we are developing matched DNA case-control studies in ready-made plates. This will enable researchers, even those on a limited budget, to take advantage of premium sample-sets that were once the exclusive reserve of large budget research programs," stated Dr. Krenitsky.

About BioServe

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository®, a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Contact Information: Contacts: Kevin Krenitsky Chief Executive Officer BioServe 301-470-3362 Constantine Theodoropulos Boston Communications 617-292-7319